Paola Arbour Sells 6,500 Shares of Tenet Healthcare (NYSE:THC) Stock

Key Points

• Paola Arbour sold 6,500 shares at an average price of $238.43 on March 11, generating about $1.55 million and trimming her stake by 18.16% to 29,291 shares (roughly $6.98 million).
• Tenet beat expectations and has positive analyst sentiment, reporting $4.70 EPS vs. $4.08 consensus and $5.53B revenue, setting FY2026 guidance of $16.19–$18.47 EPS while analysts hold a consensus target near $250.56 and a "Moderate Buy" rating.

Tenet Healthcare Corporation (NYSE:THC - Get Free Report) EVP Paola Arbour sold 6,500 shares of the company's stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the completion of the sale, the executive vice president directly owned 29,291 shares in the company, valued at approximately $6,983,853.13. The trade was a 18.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tenet Healthcare Price Performance

NYSE THC traded up $3.06 during trading on Friday, reaching $227.79. 1,263,646 shares of the company traded hands, compared to its average volume of 921,241. Tenet Healthcare Corporation has a 1-year low of $109.82 and a 1-year high of $247.21. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.68 and a current ratio of 1.76. The stock's 50 day moving average price is $213.46 and its two-hundred day moving average price is $203.99. The company has a market cap of $19.81 billion, a price-to-earnings ratio of 14.71, a P/E/G ratio of 1.11 and a beta of 1.39.

Tenet Healthcare (NYSE:THC - Get Free Report) last posted its earnings results on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, topping the consensus estimate of $4.08 by $0.62. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The business had revenue of $5.53 billion during the quarter, compared to the consensus estimate of $5.47 billion. During the same quarter last year, the company earned $3.44 EPS. Tenet Healthcare's revenue was up 8.9% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. As a group, analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Tenet Healthcare by 1.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company's stock valued at $1,488,484,000 after acquiring an additional 119,809 shares during the period. Boston Partners lifted its position in Tenet Healthcare by 15.7% during the 4th quarter. Boston Partners now owns 3,642,136 shares of the company's stock valued at $723,804,000 after purchasing an additional 494,581 shares during the period. AQR Capital Management LLC grew its position in shares of Tenet Healthcare by 20.3% during the 4th quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company's stock worth $448,419,000 after buying an additional 380,116 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Tenet Healthcare by 8.0% during the second quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company's stock worth $373,020,000 after buying an additional 157,109 shares during the last quarter. Finally, Norges Bank bought a new position in Tenet Healthcare in the fourth quarter valued at approximately $248,494,000. 95.44% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on THC shares. Barclays increased their target price on shares of Tenet Healthcare from $240.00 to $257.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of Tenet Healthcare from $200.00 to $230.00 and gave the stock an "overweight" rating in a report on Thursday, November 13th. Wall Street Zen raised Tenet Healthcare from a "buy" rating to a "strong-buy" rating in a report on Sunday, March 1st. TD Cowen reaffirmed a "buy" rating on shares of Tenet Healthcare in a report on Thursday, February 12th. Finally, Royal Bank Of Canada boosted their price objective on Tenet Healthcare from $253.00 to $277.00 and gave the stock an "outperform" rating in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $250.56.

About Tenet Healthcare

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.